You are here:Home-Chemical Inhibitors & Agonists-Others-Other Targets-PCLX-001
PCLX-001

Chemical Structure : PCLX-001

CAS No.: 1215011-08-7

PCLX-001 (Zelenirstat, PCLX001)

Catalog No.: PC-72143Not For Human Use, Lab Use Only.

PCLX-001 (Zelenirstat) is a potent, selective, orally bioavailable N-myristoyl-transferases (NMT1/2) inhibitor with IC50 of 5/8 nM, respectively.

Packing Price Stock Quantity
5 mg $278 In stock
10 mg $458 In stock
25 mg $758 In stock
50 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

PCLX-001 (Zelenirstat) is a potent, selective, orally bioavailable N-myristoyl-transferases (NMT1/2) inhibitor with IC50 of 5/8 nM, respectively.
PCLX-001 selectively kills hematological cancer cell lines in comparison to cancer cell lines of other origins.
PCLX-001 selectively inhibits myristoylation in vitro and induces apoptosis in lymphoma cell lines, does not inhibit any of the 468 human kinases at 10 uM.
PCLX-001 reduces SFK levels and BCR downstream signaling.
PCLX-001 attenuates BCR downstream signaling events in BL2 lymphoma cells.
PCLX-001 selectively kills hematological cancer cells (IC50=0.166 uM) relative to benign lymphocytes in comparison to dasatinib and ibrutinib.
PCLX-001 reduces tumor volumes and leads to complete tumor regression in B-cell lymphoma xenograft models.
PCLX-001 can efficiently target breast cancer by reducing the viability of numerous breast cancer cell lines in vitro and cause disease regression in vivo in an established murine xenograft breast cancer model.

Physicochemical Properties

M.Wt 537.504
Formula C24H30Cl2N6O2S
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

2,6-Dichloro-N-[1,5-dimethyl-3-(2-methylpropyl)-1H-pyrazol-4-yl]-4-[2-(1-piperazinyl)-4-pyridinyl]benzenesulfonamide

References

1. Beauchamp E, et al. Nat Commun. 2020 Oct 22;11(1):5348.

2. Mackey JR, Lai J,et al. Breast Cancer Res Treat. 2021 Feb;186(1):79-87.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: